In an interview with Swiss newspaper Finanz und Wirtschaft, Roche (OTCQX:RHHBY -0.4%)
CEO Severin Schwan said he “sees a chance” that revenues will ramp up
after 2022 driven by demand for new products. Additional points:
Tecentriq has “big” potential, can envision market boosting sales estimates after study results.
Company has “very early stage” program for COVID-19 antiviral but it will take “years” for clinical studies to wind up.
Expects 2020 revenue erosion of $4B related to Avastin, Mabthera and Herceptin.
https://seekingalpha.com/news/3580850-roche-revenue-may-pick-up-after-2022-ceo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.